Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Missed estimates and weak quarter: Sera reported ($0.17) EPS, missing consensus by $0.01, with Q1 revenue just $14,000 and a net loss of $8.4 million, and management warned 2026 revenue could remain uneven as commercialization ramps.
• Commercialization and evidence build: The company launched a third partnership program (over 350 providers across three states), is engaging with 13 payers in 15 states, and strengthened its clinical case after publication of the PRIME trial with additional analyses and the PREPARE survey slated to support reimbursement and guideline inclusion.
• Cost-cutting and runway preserved: After a business realignment aimed at nearly $10 million in annualized operating expense reductions, Sera reported $86.8 million in cash and securities and expects a cash runway through 2029, while shifting R&D toward external partnerships.

Sera Prognostics (NASDAQ:SERA - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01), FiscalAI reports. Sera Prognostics had a negative net margin of 39,417.29% and a negative return on equity of 37.50%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.07 million.

Here are the key takeaways from Sera Prognostics' conference call:

• Launched a third partnership program (reaching over 350 providers across three states) and is engaging with 13 payers in 15 states, pursuing a paced rollout of ~one large partner program per quarter to drive provider adoption and referral pathways for PreTRM.
• Strengthened the evidence base after publication of the full PRIME trial and related European commentary, with the PREPARE survey accepted for publication and multiple PRIME sub‑analyses (including health economics and Medicaid outcomes) planned for 2026 to support reimbursement and guideline inclusion.
• Financial performance remains modest: Q1 revenue was just $14,000 (down from $38,000 a year ago) and net loss was $8.4 million, and management cautioned 2026 revenue may stay uneven as commercialization and reimbursement efforts ramp.
• Completed a business realignment to shift spend toward commercialization and medical engagement, targeting nearly $10 million in annualized operating expense reductions and reporting $86.8 million in cash and securities with an expected cash runway through 2029.
• Strategic pivot reduces internal R&D/Clinical Ops headcount and emphasizes external partnerships to develop future tests, a move that could speed market access but also lowers internal development capacity until new collaborations are formalized.

Sera Prognostics Price Performance

NASDAQ SERA traded down $0.07 during trading hours on Wednesday, reaching $1.81. The company's stock had a trading volume of 45,619 shares, compared to its average volume of 22,376. Sera Prognostics has a fifty-two week low of $1.37 and a fifty-two week high of $4.09. The company's 50-day moving average is $2.07 and its two-hundred day moving average is $2.77.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Sera Prognostics in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.

Insider Buying and Selling

In related news, CEO Zhenya Lindgardt sold 22,639 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total value of $43,014.10. Following the sale, the chief executive officer directly owned 741,287 shares of the company's stock, valued at approximately $1,408,445.30. This represents a 2.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have sold 53,133 shares of company stock valued at $103,854. 11.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sera Prognostics

Several hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC boosted its stake in shares of Sera Prognostics by 8.9% during the 3rd quarter. Squarepoint Ops LLC now owns 93,063 shares of the company's stock worth $285,000 after purchasing an additional 7,643 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of Sera Prognostics by 1.9% during the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company's stock worth $2,000,000 after purchasing an additional 12,439 shares during the last quarter. Lido Advisors LLC acquired a new stake in shares of Sera Prognostics during the 3rd quarter worth about $68,000. Cetera Investment Advisers acquired a new stake in shares of Sera Prognostics during the 4th quarter worth about $74,000. Finally, Barclays PLC boosted its stake in shares of Sera Prognostics by 267.4% during the 4th quarter. Barclays PLC now owns 36,722 shares of the company's stock worth $108,000 after purchasing an additional 26,726 shares during the last quarter. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company's flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman's risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.